Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer

Targeted Oncology

Volumn 8, Issue 4, 2013, Pages 291-294

  Petrelli, Fausto ^a   Borgonovo, Karen ^a   Lonati, Veronica ^a   Elia, Stefano ^b   Barni, Sandro ^a  

^a TREVIGLIO HOSPITAL   (Italy)

^b Ospedale di Esine   (Italy)

Author keywords

Breast cancer; Catumaxomab; EpCAM; Intraperitoneal; Liver metastases; Locoregional effects; Malignant ascites; Systemic effects

Indexed keywords

CAPECITABINE; CATUMAXOMAB; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; FULVESTRANT; GEMCITABINE; LETROZOLE; MEGESTROL; METHOTREXATE; METOCLOPRAMIDE; ONDANSETRON; PACLITAXEL; PARACETAMOL; PREDNISOLONE;

ABDOMINAL CANCER; ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL DRAINAGE; ABDOMINAL PAIN; AGED; ANOREXIA; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; FOLLOW UP; GASTRIC METASTASIS; HUMAN; LIVER FAILURE; LIVER METASTASIS; LYMPH NODE DISSECTION; MALIGNANT ASCITES; MASTECTOMY; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; PAIN; PARACENTESIS; PLEURA EFFUSION; PRIORITY JOURNAL; TREATMENT RESPONSE; VOMITING;

AGED; ANTIBODIES, BISPECIFIC; ASCITES; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; LIVER NEOPLASMS; TREATMENT OUTCOME;

EID: 84890561529     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-012-0240-y     Document Type: Article

References (14)

1. Ayantunde AA, Parsons S (2007) Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 18:945-949
2. Tamsma J (2007) The pathogenesis of malignant ascites. Cancer Treat Res 134:109-118
3. Smith EM, Jayson GC (2003) The current and future management of malignant ascites. Clin Oncol (R Coll Radiol) 15:59-72
4. Woopen H, Sehouli J (2009) Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer Res 29:3353-3359
5. Becker G, Galandi D, Blum HE (2006) Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 42:589-597
6. Alt-Epping B, Nauck F (2010) Palliativmedizinische Behandlungsoptionen. In: Kiewe P, Thiel E (eds) Peritonealkarzinose und maligner aszites. UNI-MED Verlag, Berlin, pp 87-90
7. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 127:2209-2221
8. Seimetz D, Lindhofer H, Bokemeyer C (2010) Development and approval of the trifunctional antibody catumaxomab (anti-EpCAMxanti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 36:458-467
9. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S (2004) Frequent EpCAM protein expression in human carcinomas. Hum Pathol 35:122-128
10. Schmidt M, Hasenclever D, Schaeffer M, Boehm D, Cotarelo C, Steiner E, Lebrecht A, Siggelkow W, Weikel W, Schiffer-Petry I, Gebhard S, Pilch H, Gehrmann M, Lehr HA, Koelbl H, Hengstler JG, Schuler M (2008) Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. Clin Cancer Res 14:5849-5855
11. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, Maurer R, Metzger U, von Castelberg B, Bart R, Stopatschinskaya S, Köchli OR, Haas P, Mross F, Zuber M, Dietrich H, Bischoff S, Mirlacher M, Sauter G, Gastl G (2004) High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 86:207-213
12. Ruf P, Kluge M, Jäger M, Burges A, Volovat C, Heiss MM, Hess J, Wimberger P, Brandt B, Lindhofer H (2010) Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. Br J Clin Pharmacol 69:617-625
13. Wimberger P, Heubner M, Lindhofer H, Jäger M, Kimmig R, Kasimir-Bauer S (2009) Influence of catumaxomab on tumor cells in bone marrow and blood in ovarian cancer. Anticancer Res 29:1787-1791
14. Woopen H, Pietzner K, Darb-Esfahani S, Oskay-Oezcelik G, Sehouli J (2012) Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature. Med Oncol. doi: 10.1007/s12032-012-0285-x